

- Pulmonary fibrosis
bleomycin-related, 621
bronchiectasis in, 1694
chemotherapy-associated, 103e-8, 103e-13
dyspnea in, 47e-1t, 47e-4
idiopathic. *See* Idiopathic pulmonary fibrosis
as late consequence of cancer/cancer therapy, 621
pathophysiology of, 306e-3, 1709f
pulmonary function values in, 306e-5, 306e-5f
radiation-induced, 103e-4
in systemic sclerosis, 2157–2158, 2158f
- Pulmonary function tests
in asthma, 1675, 1675f
common abnormalities in, 306e-5f
in COPD, 1704, 1704t
in hypersensitivity pneumonitis, 1682
in interstitial lung diseases, 1710
in occupational lung disease, 1687
in pulmonary hypertension, 1656–1657
in respiratory disease evaluation, 1662, 1693
- Pulmonary heart disease. *See* Cor pulmonale
- Pulmonary hypertension, **1655**
arterial. *See* Pulmonary arterial hypertension
clinical features of, 1655
chest pain, 96t, 98
dyspnea, 47e-2, 47e-2t, 1655
tricuspid regurgitation, 1655
diagnosis of, 1655–1657
chest radiography, 47e-4, 1658f
CT, 1656, 1658f
ECG, 269e-11f
echocardiography, 271e-9f, 271e-9v, 1655–1656, 1657f
heart sounds, 1447, 1655
pulmonary function tests, 1656–1657
high-altitude, 476e-6
in left heart disease, 1658–1659
in lung disease, 1659
in mitral stenosis, 1539
pathogenesis of, 1655, 1657t
in pregnancy, 47
Raynaud's phenomenon in, 1649
in sarcoidosis, 1659
in schistosomiasis, 1659
in sickle cell disease, 1659
in sleep-disordered breathing, 1657
thromboembolic, 1659
treatment of, 1660
- Pulmonary infarction, 105, 1632
- Pulmonary infiltrates with eosinophilia
acute eosinophilic pneumonia, 1684, 1684t
allergic bronchopulmonary aspergillosis.
See Allergic bronchopulmonary aspergillosis (ABPA)
C. pseudotuberculosis, 980
chronic eosinophilic pneumonia, 1685
classification of, 1683–1684
disorders associated with, 1684t
drug- and toxin-induced, 1687
eosinophilic granulomatosis with polyangiitis.
See Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
global considerations in, 1687
hypereosinophilic syndromes. *See* Hypereosinophilic syndromes (HES)
infectious causes of, 1685–1686, 1685t
pathophysiology of, 1683
- Pulmonary Langerhans cell histiocytosis, 1713
- Pulmonary lymphangioleiomyomatosis, 308e-5f, 1714–1715
- Pulmonary mass/nodule. *See also* Lung cancer
hamartoma, 515
solitary, 515–516, 516t, 517f, 1666
- Pulmonary rehabilitation, 47e-4, 1706
- Pulmonary risk assessment, preoperative, 54–55, 54t
- Pulmonary vascular resistance, 1746, 1748t
- Pulmonary veins, anomalous drainage of, 271e-10f
- Pulmonic regurgitation, **1550**
clinical features of, 1550
etiology of, 1547t, 1550
heart sounds/murmur in, 51e-6–7, 1449, 1550
treatment of, 1550
- Pulmonic stenosis, **1549**
in carcinoid syndrome, 564
clinical features of, 1549
congenital, 1525
diagnosis of, 1524–1525, 1525f, 1549–1550
etiology of, 1547t, 1549
heart sounds/murmur in
auscultation of, 1447, 1448, 1525, 1549–1550
duration of, 51e-3, 51e-4f
intensity and radiation of, 51e-2f
timing of, 51e-1f
pathophysiology of, 1549
treatment of, 296e-5, 1525f, 1550
- Pulp, dental, 236
- Pulpitis, 236, 1097
- “Pulsatile tinnitus,” 2586
- Pulse
assessment of, 1445–1446, 1445f, 1446f
in peripheral artery disease, 1447, 1447f, 1643
- Pulsed-field gel electrophoresis, 150e-8
- Pulsed wave Doppler, 270e-2, 270e-2f. *See also* Echocardiography
- Pulseless disease. *See* Takayasu's arteritis
- Pulseless electrical activity, 1764, 1769–1770, 1769f
- Pulse oximetry, 1662, 1733
- Pulse pressure, 292e-1v, 1611, 1729, 1732f
- Pulsus alternans, 1446
- Pulsus paradoxus
in cardiogenic shock, 1750
in dyspnea evaluation, 47e-3
echocardiography in, 271e-8f, 271e-8v
etiology of, 1445
measurement of, 1445
in obstructive lung disease, 1662
in pericardial tamponade, 1450
- Pulsus parvus et tardus, 1445, 1531
- Punch biopsy, 340
- “Punch drunk” syndrome. *See* Chronic traumatic encephalopathy
- Punding, 2615
- Punta Toro virus, 1309t, 1318
- Pupil(s)
assessment of, 195–197, 196f
in coma, 1774, 1774f
inequality in size of, 196
- Pure alexia without agraphia, 177t, 178–179
- Pure autonomic failure (PAF), 2642
- Pure red cell aplasia, **667**
classification of, 668t
clinical associations of, 669
congenital (Diamond-Blackfan anemia), 669, 669t
definition of, 668
differential diagnosis of, 668
drug-induced, 44, 668t
etiology of, 668
parvovirus B19 infection and, 138e-6, 668, 668f, 1196
thymoma and, 123e-2, 668
treatment of, 668–669
- Pure tone audiometry, 222
- Pure white cell aplasia, 667
- Pure word deafness, 177t, 178
- Purified protein derivative (PPD)/tuberculin skin test (TST)
in fever of unknown origin, 138
in latent TB infection, 1114, 1121
limitations of, 770
in nontuberculous mycobacterial infections, 1131
in TB diagnosis, 1107
- Purine metabolism, 431e-2, 431e-3
- Purine metabolism disorders, **431e-5**
inborn, 431e-3t, 431e-5–6
in SCID, 375e-1, 2108
- Purine nucleoside phosphorylase deficiency, 431e-3t, 2108
- Purkinje fibers, 265e-12, 273e-1
- Purple sticky (*Salvia divinorum*), 469e-4
- Purpura, 127, 135, **367**
nonpalpable, 127, 367–368
palpable, 127, 364t, 368–369
posttransfusion, 138e-5
senile, 403–404
solar, 367
wet, 727, 728
- Purpura fulminans
clinical features of, 133t
epidemiology of, 133t
etiology of, 780t, 782
genetic considerations in, 368, 737, 744
meningococcal, 998
treatment of, 738, 780t, 782
- Purtscher's like retinopathy, 40e-4
- Purpuru. *See* Pinta
- Pus, 416
- Push enteroscopy, 279, 1881
- Push packages, 261e-9
- Pustular lesions, 339t, **356**, 382
- Pustular psoriasis. *See* Psoriasis, pustular
- “Put Prevention into Practice” program, 30
- Puumala virus, 1307t
- PUVA photochemotherapy
action of, 391
adverse effects of, 348
for atopic dermatitis, 354t
for cutaneous T-cell lymphoma, 391
for morphea, 376
for psoriasis, 348, 354t, 391
for vitiligo, 358t, 391
- PVCs. *See* Premature ventricular contractions (PVCs)
- pVHL (elongin), 2343
- PVL (Panton-Valentine leukocidin) toxin, 807, 830, 956
- PVNS (pigmented villonodular synovitis), 2246, 2247f
- P wave, 273e-1
- Pyelonephritis. *See also* Urinary tract infections (UTIs)
actinomycotic, 1089
clinical features of, 863, 864f
definition of, 861
emphysematous, 863, 864f
M. hominis, 1165
in pregnancy, 49–50
prognosis of, 868
renal biopsy in, 62e-10f
risk factors for, 862
treatment of, 867
xanthogranulomatous, 863, 864f
- Pyknodysostosis, 426e-4–5
- Pyoderma. *See* Impetigo
- Pyoderma gangrenosum
clinical features of, 76e-17f, 369, 369t
differential diagnosis of, 366
diseases associated with, 369
drug-induced, 379
in IBD, 1957
- Pyoderma vegetans, in IBD, 1958
- Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome, 372e-8t, 422, 2215
- Pyogenic granuloma, 237, 380, 380f
- Pyomyositis, 831, 958, 2198
- Pyostomatitis vegetans, in IBD, 1958
- Pyramidal (corticospinal) system, 155f
- Pyrantel pamoate, 246e-6t, 246e-12
- Pyrazinamide
action of, 205e-4
adverse effects of, 205e-4–5, 1117
dosage of, 205e-4
genetic variations in response to, 39t
pharmacology of, 205e-4
in pregnancy, 205e-5
resistance to, 205e-5, 1118
for TB, 205e-2t, 205e-4–5, 1115–1117, 1115t
for tuberculous meningitis, 898
- Pyrethrins, 2746
- Pyridostigmine
adverse effects of, 2704
for gastroparesis, 260t, 261